+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies

  • Book

  • January 2015
  • Elsevier Science and Technology
  • ID: 2986237

Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies takes a look at the current strategies, successes and challenges involved with the development of novel formulations of biologics, vaccines and cancer therapy. This thorough reference on the latest trends in the development of diverse modalities will appeal to a broad community of scientists, students and clinicians. Written by leading authors across academia and industry, this book covers important topics such as unique drug delivery devices, non-parenteral delivery trends, novel approaches to the treatment of cancer, immunotherapy and more. It includes real-world cases and examples which highlight formulations with therapeutic proteins, monoclonal antibodies, peptides and biobetters, as well as cases on novel vaccines formulations including evolving pathogens, novel modalities of vaccines, universal vaccines. This book is a thorough and useful resource on the development of novel biologics, vaccines and cancer therapies.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

Section I: NOVEL THERAPEUTIC APPROACHES 1. Clinical Considerations in the Design, Evaluation and Development of Novel Therapies 2. New Era in Gene Therapy 3. Advances in Nanotechnology-Based Drug Delivery Platforms and Novel Drug Delivery Systems 4. Novel Approaches for the Delivery of Biologics to the Central Nervous System 5. Trends in Nonparenteral Delivery of Biologics, Vaccines and Cancer Therapies

Section II: NOVEL APPROACHES FOR BIOLOGICS 6. Novel Generation of Antibody-Based Therapeutics 7. Novel Approaches in Discovery and Design of Antibody-Based Therapeutics 8. Novel Therapeutic Proteins and Peptides 9. Biobetter Biologics

Section III: NOVEL APPROACHES FOR VACCINES 10. Vaccines Against Non-Infectious, Non-Cancer Novel Targets 11. Winning a Race Against Evolving Pathogens with Novel Platforms and Universal Vaccines 12. Prime-Boost Vaccination: Impact on the HIV Vaccine Field


IV.I Novel Therapeutic Approaches and Targets for Cancer 13. Personalized Therapies for Cancer Treatment 14. Hunting Molecular Targets for Anticancer Reagents by Chemical Proteomics

IV.II Novel Immunotherapies for Cancer 15. Cancer Vaccines 16. T-Cell Immunotherapy for Cancer 17. Immunostimulators and Immunomodulators in Cancer Treatment

IV.III Novel Approaches for Cancer Therapy with Small Molecules 18. Long-Circulating Therapies for Cancer Treatment 19. Recent Advances and Trends in the Brain Delivery of Small Molecule Based Cancer Therapies


Manmohan Singh PhD, Head of Global Manufacturing Technology Development & Adjuvant Formulation & Technology, Novartis Vaccines and Diagnostics; Adjunct Professor, University of North Carolina at Chapel Hill. Manmohan Singh, Ph.D. is a well-known expert in the area of vaccine formulations and adjuvant research and has been working in vaccine R&D for the last 20 years. He has authored over 120 peer reviewed manuscripts, review articles and book chapters in this area. Dr. Singh is on the editorial board of 9 International Journals . He is also the editor of several books on vaccine delivery systems and adjuvants. He is currently working as the Head of Global Drug Product Development at Novartis Vaccines in Holly Springs, NC, U.S.A. Maya Salnikova PhD, Principal Scientist and Formulation Group Leader, Novartis Vaccines and Diagnostics, Holly Springs, NC. Maya Salnikova, Ph.D. is a well-known expert in the area of biologics, biosimilars and vaccine formulations. She has been working on development of novel formulations for the past 10 years in academia and industry. She has authored over 20 peer reviewed articles and book chapters. Dr. Salnikova is on the board of reviewers for Journal of Pharmaceutical Sciences and has contributed in organizing of international conferences. She is currently working as Drug Product Development Lead at Novartis Vaccines in Holly Springs, NC, U.S.A.